skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Impact of genetic polymorphisms on clinical response to antithrombotics

Review

(2514) Views  (863) Full article downloads

Authors: Kena J Lanham, Julie H Oestreich, Steven P Dunn, et al

Published Date June 2010 Volume 2010:3 Pages 87 - 99
DOI: http://dx.doi.org/10.2147/PGPM.S9597

Kena J Lanham1,2, Julie H Oestreich3, Steven P Dunn1,2, Steven R Steinhubl4

1Pharmacy Services, UK HealthCare, University of Kentucky, Lexington, Kentucky, USA; 2Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA; 3Department of Pharmacy Practice, College of Pharmacy, University of Nebraska, Omaha, Nebraska, USA; 4The Medicines Company, Zurich, Switzerland and The Geisinger Clinic, Danville, Pennsylvania, USA

Abstract: Antithrombotic therapy, including anticoagulants as well as antiplatelet drugs, is an important component in the treatment of cardiovascular disease. Variability in response to such medications, of which pharmacogenetic response is a major source, can decrease or enhance the benefits expected. This review is a comprehensive assessment of the literature published to date on the effects of genetic polymorphisms on the actions of a variety of antithrombotic medications, including warfarin, clopidogrel, prasugrel, and aspirin. Literature evaluating surrogate markers in addition to the impact of pharmacogenetics on clinical outcomes has been reviewed. The results of the studies are conflicting as to what degree pharmacogenetics will affect medication management in cardiovascular disease. Additional research is necessary to discover, characterize, and prospectively evaluate genetic and non-genetic factors that impact antithrombotic treatment in order to maximize the effectiveness and limit the harmful effects of these valuable agents.

Keywords: aspirin, warfarin, clopidogrel, prasugrel, pharmacogenetic, antithrombotic, antiplatelet








Readers of this article also read:

Integrating epigenomics into pharmacogenomic studies
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Gene polymorphisms in association with self-reported stroke in US adults
Antiplatelet agents and proton pump inhibitors – personalizing treatment
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions